Is Chlamydia an STD or STI? Here’s What It Means

Chlamydia is both an STD and an STI. The two labels describe the same condition caused by the same bacterium, Chlamydia trachomatis. The difference is in the words themselves: “sexually transmitted infection” emphasizes that a person can carry and pass on the organism without ever feeling sick, while “sexually transmitted disease” implies symptoms and illness. Over the past two decades, health organizations have gradually shifted toward “STI” as the default term, and chlamydia is one of the clearest examples of why that shift happened.

Why Health Organizations Started Saying STI Instead of STD

The push to replace “STD” with “STI” started in clinical and public health circles, driven by the idea that “infection” more accurately describes what is going on in most cases. When someone contracts chlamydia, they are infected with a bacterium. Whether that infection ever progresses to a recognizable disease with symptoms is a separate question, and for most people with chlamydia, the answer is no. Calling it a “disease” when the majority of people carrying it have no symptoms struck many clinicians as misleading, so “STI” gained traction as a more precise term.

There was also a hope that the word “infection” would feel less stigmatizing than “disease.” Research into whether that hope holds up has been limited. A study of late adolescents found that the shift from STD to STI was largely based on conjecture that the newer term would reduce stigma, with little evidence about how the public actually perceives the difference.¹ In practice, most people use STD and STI interchangeably, and no doctor will misunderstand you if you say one instead of the other. The important thing is not which label you use when talking to your healthcare provider, but understanding what chlamydia actually does once it enters your body.

Most People with Chlamydia Have No Symptoms

This is the single most important fact behind the STD-versus-STI debate, and it is the reason chlamydia is such a persistent public health problem. The majority of chlamydia infections produce no noticeable symptoms at all. A systematic review of women in low- and middle-income countries found that roughly 61% of chlamydia infections were asymptomatic.² In men, the numbers can be even higher. A study of male college cadets found that over 93% of those who tested positive for chlamydia had no symptoms whatsoever.³

This is not just a statistical curiosity. It is the reason chlamydia spreads as widely as it does. People who feel perfectly fine have no reason to seek testing or treatment, and they unknowingly pass the bacterium to sexual partners. A follow-up study of asymptomatic women with chlamydia found that nearly half of them cleared the infection on their own within a year without developing any clinical symptoms or pelvic inflammatory disease.⁴ That sounds reassuring at first glance, but it also means the other half continued to carry an active infection that could still cause damage and be transmitted to others. And while spontaneous clearance happened in that study, relying on your immune system to handle chlamydia is a gamble with real stakes, because the complications of untreated infection can be serious.

How Chlamydia Works Inside the Body

Chlamydia trachomatis is an unusual bacterium. It cannot survive on its own outside of human cells, which makes it what microbiologists call an obligate intracellular pathogen. It has a two-phase life cycle: one form, called the elementary body, is the infectious particle that enters a cell, while the other form, called the reticulate body, is the version that multiplies inside the cell but cannot infect new cells on its own.⁵ Once the replicating form has produced enough copies, it converts back into infectious particles, the host cell bursts open, and those particles go on to infect neighboring cells.

This cycle explains a few things about chlamydia’s behavior. The bacterium hides inside your cells, which makes it partially invisible to parts of your immune system. That is one reason infections can persist for months without triggering obvious inflammation or symptoms. It also explains why chlamydia does not behave like a typical skin infection with redness and pus at the site of entry. The damage tends to be slow, internal, and cumulative.

What Happens When Chlamydia Goes Untreated

The consequences of untreated chlamydia fall disproportionately on women, and they center on the reproductive tract. The most well-known complication is pelvic inflammatory disease, which occurs when the infection ascends from the cervix into the uterus and fallopian tubes. Chlamydia is one of the most frequent causes of this condition.⁶ Pelvic inflammatory disease can cause chronic pelvic pain, but its most consequential effect is scarring in the fallopian tubes, which can block the passage of eggs and lead to infertility or ectopic pregnancy.

The data on these risks is consistent across multiple large studies. A retrospective cohort found that women who tested positive for chlamydia had more than double the risk of pelvic inflammatory disease compared to those who tested negative, along with a meaningfully elevated risk of ectopic pregnancy and infertility.⁷ A long-term prospective study following women from 2008 to 2022 found that chlamydia positivity was strongly associated with tubal factor infertility, with a nearly threefold increase in risk.⁸ A meta-analysis of observational studies confirmed the pattern, finding that evidence of past chlamydia infection (detected through blood antibodies) was significantly associated with both tubal infertility and ectopic pregnancy.⁹

In men, the complications of untreated chlamydia are generally less severe but not trivial. The infection can cause epididymitis, an inflammation of the tube that stores sperm behind the testicle, which produces pain and swelling and can in rare cases affect fertility. Reactive arthritis, a condition where joint inflammation develops as an immune response to the infection, is another recognized complication in both sexes.

Chlamydia Beyond the Genitals

When people think of chlamydia, they picture a genital infection. But C. trachomatis can also infect the throat and rectum, and these extragenital infections are frequently missed because they are usually silent. A review of the literature found that extragenital chlamydia infections are often asymptomatic and occur even in the absence of reported risk behaviors like receptive anal or oral sex.¹⁰ This matters because standard testing typically involves only a genital swab or urine sample, which would completely miss a rectal or pharyngeal infection.

The problem is especially well-documented among men who have sex with men, where significant rates of asymptomatic rectal and throat chlamydia infections have been found, with or without a concurrent genital infection. Because extragenital sites are not routinely screened, many of these infections go undiagnosed.¹¹ If you have had oral or anal sex and are getting tested for chlamydia, it is worth specifically asking your provider to test those sites. A urine test alone will not catch what it cannot reach.

There is also a less common but more aggressive variant. Different strains of C. trachomatis cause different diseases. The strains labeled L1 through L3 cause lymphogranuloma venereum (LGV), which can invade lymph nodes and cause much more serious tissue damage than typical genital chlamydia. In contrast, the more common strains (serovars A through K) produce only superficial mucosal infections.¹² LGV is rare in most high-income countries but has been increasing in outbreaks among men who have sex with men. It requires a longer course of antibiotics than standard chlamydia.

Chlamydia and the Eyes

The same bacterium that causes genital chlamydia is also responsible for trachoma, the world’s leading infectious cause of blindness. The eye-affecting strains are different from the genital ones, but genital strains (serovars D through K) can also cause eye infections, typically through hand-to-eye transfer of infected secretions. In adults, this manifests as inclusion conjunctivitis, a chronic redness and irritation of the eye. In newborns exposed during delivery, it can cause a more acute eye infection called ophthalmia neonatorum.¹³ This connection between genital and ocular disease further illustrates why thinking of chlamydia as only a “below the belt” problem sells the infection short.

Treatment Has a Clear Winner

Chlamydia is curable with antibiotics, and treatment is straightforward. For years, two options were considered roughly equivalent: a single dose of azithromycin (the one-and-done pill) or a seven-day course of doxycycline. That equivalence has been challenged by more recent evidence, and doxycycline is now clearly favored.

A randomized trial published in the New England Journal of Medicine found zero treatment failures in the doxycycline group, compared to a 3.2% failure rate with azithromycin for urogenital chlamydia.¹⁴ The gap widens considerably for rectal chlamydia. A study of women with rectal chlamydia found that azithromycin achieved only about a 79% cure rate versus over 95% with doxycycline.¹⁵ A randomized trial among men who have sex with men found an even starker difference at the rectal site: 100% cure with doxycycline versus 74% with azithromycin.¹⁶

The practical upside of azithromycin was always convenience: one dose, taken in the office, no need to remember a week of pills. But the evidence that it simply does not work as well, especially for rectal infections, has shifted guidelines. If your provider prescribes doxycycline for chlamydia, the seven-day commitment is worth it. And if you have been treated with a single dose of azithromycin in the past, that is fine for what it was, but today the standard of care has moved on.

Why Your Partner Needs Treatment Too

Getting treated for chlamydia while your sexual partner remains untreated is a recipe for reinfection. This is not a theoretical concern. It is one of the most common reasons people test positive for chlamydia a second time. The concept of expedited partner therapy was developed to address exactly this problem: when you are diagnosed, your provider gives you a prescription or medication to deliver directly to your partner, without requiring them to come in for a separate medical visit first.

Randomized trials have found that expedited partner therapy increases the rate of partner treatment and decreases reinfection with chlamydia.¹⁷ Real-world program evaluations generally confirm that more partners get treated with this approach, though not all studies show a clear drop in follow-up infection rates.¹⁸ The legality of expedited partner therapy varies by state, but in most of the United States, it is permitted. If you test positive, ask your provider whether this option is available to you.

Chlamydia During Pregnancy

Untreated chlamydia during pregnancy carries risks for both the pregnant person and the baby. The infection has been associated with premature rupture of membranes, preterm birth, and low birth weight.¹⁹ For the newborn, the primary risks during vaginal delivery are eye infection and pneumonia.²⁰ This is why routine chlamydia screening during pregnancy is standard practice. The infection is easily treated before delivery, and doing so prevents these complications.

Chlamydia and HIV Risk

Having an active chlamydia infection appears to increase susceptibility to HIV. Research has shown that cells from chlamydia-infected individuals are more vulnerable to HIV infection, with significantly higher levels of viral replication observed compared to cells from uninfected people.²¹ The exact molecular pathways are still being mapped out, but the general picture makes biological sense: chlamydia causes local inflammation and immune activation in the genital mucosa, and activated immune cells are exactly what HIV targets. This interaction adds another reason to detect and treat chlamydia promptly, especially for people at elevated risk of HIV exposure.

Why There Is No Vaccine Yet

Given how common chlamydia is and how silently it spreads, a vaccine would transform public health. But developing one has proven difficult. The challenge is partly immunological: researchers need to stimulate a specific type of protective immune response without triggering the harmful inflammatory reaction that causes the tissue scarring and damage seen in untreated infections.²² Early vaccine attempts in the 1960s, targeting trachoma (the eye disease caused by related strains), actually made some recipients worse when they were later exposed, because the vaccine provoked an immune overreaction. That history has made researchers cautious.

Several vaccine candidates are now in early clinical trials, and animal studies have shown promising results. But a licensed chlamydia vaccine remains years away at the earliest. In the meantime, screening and treatment remain the primary tools for controlling the infection’s spread, and the high asymptomatic rate means screening has to be proactive rather than symptom-driven. Current guidelines recommend annual chlamydia screening for all sexually active women under 25, as well as for older women with risk factors like new or multiple partners.

Point-of-Care Testing and Getting Results Faster

One barrier to controlling chlamydia has been the lag between testing and treatment. Standard lab-based tests are highly accurate but can take days to return results, during which time an infected person may continue to have unprotected sex or simply not return for treatment. Rapid point-of-care tests aim to close that gap. One such test, evaluated in a large multi-center study, delivered results in about 30 minutes and achieved sensitivity above 96% and specificity above 97%.²³ That kind of accuracy in a same-visit format means a person could be tested, diagnosed, and treated in a single appointment. These tests are not yet universally available, but their development represents a meaningful step toward catching more infections before they have a chance to spread or cause harm.